Canaccord Genuity Reiterates a 'Buy' on Zalicus (ZLCS); Focus Shifts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
McNicoll Lewis & Vlak Downgrades Zalicus (ZLCS) to Hold
September 10, 2012 3:08 PM EDTMcNicoll Lewis & Vlak downgraded Zalicus (NASDAQ: ZLCS) from Buy to Hold with a price target of $1.00 following phase 2b trial results from Synavive which were statistically significant but missed a key secondary endpoint.
For an analyst ratings summary and ratings... More
Unusual 11 Mid-Day Movers 09/10: (GSI) (KSW) (BCOM) Higher; (GERN) (NDZ) (ZLCS) Lower
September 10, 2012 12:58 PM EDTGeron Corporation (Nasdaq: GERN) 56.6% LOWER; announced that, on the basis of an unplanned interim analysis, it is discontinuing its randomized Phase 2 study of imetelstat in metastatic HER2-negative breast cancer because median progression-free survival (PFS) in the imetelstat arm was shorter than in the comparator arm.
Nordion Inc. (NYSE: NDZ) 34.7% LOWER; received the decision in the confidential arbitration with Atomic Energy of Canada Limited (AECL). Nordion was unsuccessful in its claim for specific performance or monetary damages relating to AECLs cancelled... More
Pre-Open Movers 9/10: (KSW) (RF) (AMD) Higher; (GERN) (ZLCS) (TITN) Lower (more...)
September 10, 2012 9:30 AM EDTGeron Corporation (NASDAQ: GERN) 47% LOWER ; Halts Imetelstat Study in HER2-Negative Breast Cancer; Cites Median PFS in... More
Zalicus (ZLCS) Free Falls on Trade Resumption
September 10, 2012 8:33 AM EDTZalicus Inc. (Nasdaq: ZLCS) has resumed trading and is down 28 percent following phase 2b trial results from Synavive which were statistically significant but missed a key secondary endpoint.... More
